Drug Discovery

BridgeBio Pharma raises $299.2m in financing round

BridgeBio Pharma, a clinical-stage biopharmaceutical firm focused on the development of medicines for genetic diseases, has secured $299.2m funds to advanced its existing drug research and development programs.

GSK closes acquisition of Tesaro for $5.1bn

British drugmaker GlaxoSmithKline (GSK) has completed the acquisition of the US-based oncology-focused biopharmaceutical firm Tesaro for $5.1bn (£4bn).

Nash’s NASH NP-160 shows repeated positive results in second pre-clinical study

Nash Pharmaceuticals, a subsidiary of Breathtec Biomedical, has announced that its lead compound for non-alcoholic steatohepatitis (“NASH”) NP-160 showed repeated positive results in a recently completed study investigating its therapeutic effects in the widely used STAM mouse model from SMC Laboratories.

Kyn Therapeutics, Celgene partner on immuno-oncology therapies development

Kyn Therapeutics, a US-based clinical-stage biotech company, has entered into a global collaboration with biopharma major Celgene to develop immuno-oncology therapies.

Juvenescence closes first tranche of series B financing for further growth and development

Juvenescence, a biopharmaceutical company focused on modifying ageing and age-related disease, has closed the first tranche of its Series B financing, in the amount of $46m.

Sanofi to use Biomunex’s BiXAb platform to generate antibody therapeutics

Biomunex Pharmaceuticals has signed a licensing agreement with Sanofi for the development of bi-specific and multi-specific antibody therapeutics.

Bioharmony, Boehringer to advance bacteriophage lysin therapeutics to treat MDR bacterial infections

Bioharmony Therapeutics, a biopharmaceutical company focusing on the development of novel therapeutics for hard to treat bacterial infections, has entered into a collaborative research and licensing agreement with Boehringer Ingelheim to develop bacteriophage lysins for the treatment of multidrug resistant (MDR) Acinetobacter infections, a frequent cause of hospital-acquired pneumonia and life-threatening blood or wound infections.

Ascletis and Alphamab sign licensing deal for anti-PD-L1 to treat hepatitis B and other viral diseases

Ascletis Pharma (Ascletis, 1672.HK) and Suzhou Alphamab jointly announce that Ascletis' subsidiary and Alphamab have entered into a strategic collaboration and exclusive licensing agreement for anti-PD-L1 KN035 to treat hepatitis B and other viral diseases in Greater China (Ascletis code: ASC22).

Charles River, Atomwise collaborate on AI-driven drug discovery

Charles River Laboratories International has collaborated with Atomwise on integrated and artificial intelligence (AI)-driven drug discovery.